Pfizer's Paxlovid Scores FDA Approval, First Oral Antiviral For COVID-19 In US

The FDA has authorized the emergency use of Pfizer Inc's PFE Paxlovid (nirmatrelvir, PF-07321332) tablets and ritonavir tablets) for mild-to-moderate COVID-19 in adults and pediatric patients.

  • The approval comes for patients aged 12 years and older weighing at least 40 kg, who are at high risk for progression to severe COVID-19, including hospitalization or death. 
  • The emergency use nod is based on clinical data from EPIC-HR study, showing Paxlovid reduced risk of hospitalization or death by 89% (within three days of symptom onset) and 88% (within five days of symptom onset) compared to placebo.
  • Related: UK Calls For Additional Doses Of COVID-19 Antivirals From Merck, Pfizer.
  • With Paxlovid now authorized for emergency use, Pfizer stands ready to start delivery in the U.S immediately.
  • In November 2021, Pfizer announced an agreement with the U.S. government to supply 10 million treatment courses of Paxlovid, with delivery fulfillment expected to be completed in 2022.
  • Pfizer is also raising its production projections from 80 million to 120 million courses of Paxlovid by the end of 2022.
  • Price Action: PFE shares are up 1.99% at $60.13 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAMoversTrading IdeasGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!